The large-scale validation of ‘Immunoscore’, which quantifies CD3+ and CD8+ lymphocytes in the tumor center and invasive margin, showed that Immunoscore could predict the risk of recurrence with higher risk contribution than other clinical parameters including the TNM classification system7. This evidence concerns the gene CD8A and neoplasm.